Abstract:P>Background and objective: CYP2C9 is the major contributor to gliclazide metabolic clearance in vitro, while the pharmacokinetics of gliclazide modified release are affected mainly by CYP2C19 genetic polymorphisms in vivo. This study aims to investigate the influence of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers. Methods: Eighteen healthy Han subjects with various combinations of CYP2C9 and CYP2C19 genotypes received 80 mg gliclazide. Plasma gliclazide concentrations were measured by a liquid chromatography-tandem mass spectrometry method for 84 h and plasma glucose and insulin levels were measured up to 15 h post-dose. Results and discussion: There was no difference in either pharmacokinetic and or pharmacodynamic parameters of gliclazide when group A (CYP2C9*1/*1, CYP2C19 extensive metabolizers) was compared with group B (CYP2C9*1/*3, CYP2C19 *1/*1). When group C (CYP2C9*1/*1 and CYP2C19 poor metabolizers) was compared with group A, the AUC(0-infinity) and C(max) in group C were significantly higher [83 center dot 94 +/- 40 center dot 41 vs. 16 center dot 39 +/- 5 center dot 10 mu g center dot h/mL (P = 0 center dot 000) and 1 center dot 50 +/- 0 center dot 85 vs. 0 center dot 45 +/- 0 center dot 18 mu g/mL (P = 0 center dot 000)], and the oral clearance was significantly lower [1 center dot 17 +/- 0 center dot 63 vs. 5 center dot 38 +/- 1 center dot 86 L/h (P = 0 center dot 000)]. The half-life of gliclazide was also significantly prolonged in group C subjects when compared with that of group A (33 center dot 47 +/- 12 center dot 39 vs. 19 center dot 34 +/- 10 center dot 45 h), but the difference was not significant (P = 0 center dot 052). The increase in serum glucose level at 11 h after dosing (Delta C(glu11)) in group C was significantly higher than that of group A (-1 center dot 08 +/- 0 center dot 42 vs. 0 center dot 22 +/- 1 center dot 01 mmol/L, P = 0 center dot 022). The corresponding insulin levels showed no difference between the two groups. Conclusion: CYP2C9*3 was not associated with any change in the disposition of gliclazide. CYP2C19 polymorphisms appear to exert the dominant influence on the pharmacokinetics of gliclazide in healthy Chinese Han subjects, and may also affect the observed pharmacodynamics of the drug as a result.

Effect of CYP2C9,CYP2C19,CYP3A4 polymorphism on metabolism of sulfonyluea antidiabetic drugs

Recent Advance in Association Between Genetic Polymorphisms in CYP2C9 and Pharmacokinetics and Pharmacodynamics of Sulphonylureas

Effects of CYP450 genetic polymorphisms on pharmacokinetics of oral antidiabetic drugs

Progress in research of cytochrome P450 3A4 gene polymorphism

Impact of Genetic Polymorphisms of Cytochrome P450 2 C (cyp2c) Enzymes on the Drug Metabolism and Design of Antidiabetics

Effect of CYP2C19 genetic polymorphism on drug metabolism and individualized therapy

Recent Progress in Studies on Metabolism and Pharmacogenomics of Sulfonylurea Agents

Effects of CYP2C8 and SLCO1B1 Genetic Polymorphisms on Repaglinide Pharmacokinetics: A Systematic Review and Meta-Analysis

Progress and Research in Pharmacogenetics of Oral Antidiabetic Drugs

Influence of Cyp2c9 and Cyp2c19 Genetic Polymorphisms on Pharmacokinetics and Pharmacodynamics of Gliclazide in Healthy Chinese Han Volunteers

Polymorphisms of Human Cytochrome P450 2c9 and the Functional Relevance

Pharmacogenetics of Oral Antidiabetic Drugs: Potential Clinical Application

Effect of Genetic Polymorphism of CYP2C9 on Metabolism of Nonsteroidal Anti-inflammatory Drugs and Drug-Related Gastrointestinal Bleeding

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers: Influenceof CYP2C9 and CYP2C19 genetic polymorphisms

Functional evaluation of CYP2C19 and CYP3A4 gene polymorphism on ibuprofen metabolism

Study of Relationship Between Sulfonylurea Receptor Gene Polymorphism and Type 2 Diabetes

Progress in CYP3A5 Gene Polymorphism and Impact on Drug Metabolism

Advances in Study of CYP2B6 Gene Polymorphisms and Its Functional Significances

Genetic Polymorphism of CYP2C19 in Chinese Ethnic Populations

Effect of CYP2C19 Genetic Polymorphism on Lansoprazole Pharmacokinetics:A Systematic Review

Effects of Cyp2c19 Polymorphism on the Pharmacokinetics of Lansoprazole and Its Main Metabolites in Healthy Chinese Subjects